DelveInsight’s “Ovarian Cancer Market Insights, Epidemiology, and Market Forecast — 2032” report delivers an in-depth understanding of the Ovarian Cancer, historical and forecasted epidemiology as well as the Ovarian Cancer market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.
Ovarian Cancer Overview
Ovarian cancer is a type of cancer that begins in the ovaries. The ovaries — each about the size of an almond — produce eggs (ova) as well as the hormones estrogen and progesterone. Ovarian cancer is a growth of cells that forms in the ovaries. The cells multiply quickly and can invade and destroy healthy body tissue.
Ovarian Cancer Epidemiology Insights
-
As per the data given by the Surveillance, Epidemiology, and End Results (SEER) Program (2022), an estimated 19,880 cases of ovarian cancer to be recorded in the year 2022. The program also estimated a rate of 10.6 per 100,000 women per year with new cases of ovarian cancer (based on 2015–2019 cases). There were also an estimated 233,565 women living with ovarian cancer in 2019.
-
As per the data given by the Surveillance, Epidemiology, and End Results (SEER) Program (2022), an estimated 19,880 cases of ovarian cancer to be recorded in the year 2022. The program also estimated a rate of 10.6 per 100,000 women per year with new cases of ovarian cancer (based on 2015–2019 cases). There were also an estimated 233,565 women living with ovarian cancer in 2019.
-
According to statistics provided by the European Cancer Information System (ECIS) (2020), in 2020, there were about 7,162, 5,320, 5,370, 3,513, and 6,056 cases of ovarian cancer in Germany, France, Italy, Spain, and the United Kingdom, respectively.
Click here to learn more about the Ovarian Cancer Market Landscape
The Report Covers the Ovarian Cancer Epidemiology Segmented by:
-
Ovarian Cancer diagnosed incident cases
-
Total Ovarian Cancer type-specific cases
-
Total Ovarian Cancer stage-specific cases
-
Total Ovarian Cancer Line wise treated cases
Ovarian Cancer Market Outlook
The treatment goal of ovarian cancer usually is to kill the cancer cells or remove the tumor so that the cancerous cells don’t metastasize and to prevent the recurrence of cancer and slow down growth. Sometimes the aim is to treat the symptoms in case of incurable cases by using chemotherapy, radiation, hormonal therapies, targeted drugs or a combination of any of these as per the requirement. In the case of early-stage ovarian cancer, surgery is performed to remove the tumor and stage cancer followed by chemotherapy to prevent the recurrence of ovarian cancer or to shrink the tumor if the tumor could not be removed by surgery. The aim is to increase the survival rate. In advanced stages of cancer (Stage III and IV) the focus is to put the tumor into remission so that it shrinks or disappears. In the case of cancer relapse, Chemotherapy is again used as a treatment option.
At present, Avastin (bevacizumab; Genentech), Zejula (niraparib; GlaxoSmithKline), Rubraca (rucaparib; Clovis Oncology), Lynparza (AstraZeneca), are a few approved drug therapies for the treatment of Ovarian Cancer. Rubraca (Clovis Oncology), Zejula (niraparib; GlaxoSmithKline), and Lynparza (olaparib; AstraZeneca), are poly (ADP-ribose) polymerase (PARP) inhibitors indicated for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapy.
Key Companies Working in the Ovarian Cancer Market
-
AbbVie
-
Green 3 Bio Inc
-
Sanofi
-
AstraZeneca
And many others
Ovarian Cancer Therapies Covered and Analyzed in the Report:
-
Veliparib
-
Carboplatin
-
Olaparib
-
Bevacizumab
And many others
Learn more about the Key Companies and Emerging Therapies in the Ovarian Cancer Market
Table of Contents
-
Key Insights
-
Ovarian Cancer Introduction
-
Executive Summary of Ovarian Cancer
-
Disease Background and Overview
-
Epidemiology and patient population
-
Ovarian Cancer Emerging Therapies
-
Ovarian Cancer Market Outlook
-
Market Access and Reimbursement of Therapies
-
Market Drivers
-
Market Barriers
-
Appendix
-
Report Methodology
-
DelveInsight Capabilities
-
Disclaimer
Learn about the detailed offerings of the report @ Ovarian Cancer Market Outlook
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Adya Kaul
Email: Send Email
Phone: 919650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services